OBJECTIVES: The aim of the study was to explore the factors surrounding modification of the first antiretroviral (ARV) regimen where drug switch occurred 3 months or more after initiation. Reference was made to the British HIV Association (BHIVA) guidelines on HIV management. METHODS: A case note and questionnaire-based audit was carried out. RESULTS: Toxicity was the single most important reason for ARV change and was the only, or a contributory, cause in over half the patients. Virological failure, adherence issues, requirement for treatment simplification, and patient request were other significant reasons cited. In one-third of those with virological failure, six or more months had elapsed between first detection and the time of switching to a new ARV regimen. CONCLUSIONS: This audit demonstrated broad adherence to the BHIVA guidelines, although the long time before switching ARVs in the setting of virological failure was of some concern, particularly given the continuing and significant occurrence of primary ARV resistance in the UK.
OBJECTIVES: The aim of the study was to explore the factors surrounding modification of the first antiretroviral (ARV) regimen where drug switch occurred 3 months or more after initiation. Reference was made to the British HIV Association (BHIVA) guidelines on HIV management. METHODS: A case note and questionnaire-based audit was carried out. RESULTS:Toxicity was the single most important reason for ARV change and was the only, or a contributory, cause in over half the patients. Virological failure, adherence issues, requirement for treatment simplification, and patient request were other significant reasons cited. In one-third of those with virological failure, six or more months had elapsed between first detection and the time of switching to a new ARV regimen. CONCLUSIONS: This audit demonstrated broad adherence to the BHIVA guidelines, although the long time before switching ARVs in the setting of virological failure was of some concern, particularly given the continuing and significant occurrence of primary ARV resistance in the UK.
Authors: Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman Journal: Clin Infect Dis Date: 2011-03-15 Impact factor: 9.079
Authors: J Zhou; P C K Li; N Kumarasamy; M Boyd; Y M A Chen; T Sirisanthana; S Sungkanuparph; S Oka; G Tau; P Phanuphak; V Saphonn; F J Zhang; S F S Omar; C K C Lee; R Ditangco; T P Merati; P L Lim; J Y Choi; M G Law; S Pujari Journal: HIV Med Date: 2009-07-06 Impact factor: 3.180
Authors: Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn Journal: PLoS One Date: 2010-06-01 Impact factor: 3.240
Authors: Alejandro Gonzalez-Serna; Keith Chan; Benita Yip; William Chau; Rachel McGovern; Hasina Samji; Viviane Dias Lima; Robert S Hogg; Richard Harrigan Journal: J Antimicrob Chemother Date: 2014-04-15 Impact factor: 5.790